Close Menu

NEW YORK – ClinSpec Dx is developing an infrared spectroscopy-based test for diagnosing brain cancer patients at an early stage and aims to make the assay available for clinical use in Europe within the next two years.

The company spun out of the University of Strathclyde earlier this year and in partnership with the University of Edinburgh recently completed a trial of the test involving 400 patients.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.